RxSight (NASDAQ:RXST) & Edap Tms (NASDAQ:EDAP) Head to Head Contrast

Edap Tms (NASDAQ:EDAPGet Free Report) and RxSight (NASDAQ:RXSTGet Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and analyst recommendations.

Risk & Volatility

Edap Tms has a beta of -0.16, suggesting that its stock price is 116% less volatile than the S&P 500. Comparatively, RxSight has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Edap Tms and RxSight, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edap Tms 1 2 1 0 2.00
RxSight 3 10 2 0 1.93

Edap Tms currently has a consensus target price of $8.50, indicating a potential upside of 84.78%. RxSight has a consensus target price of $9.78, indicating a potential upside of 19.10%. Given Edap Tms’ stronger consensus rating and higher probable upside, analysts plainly believe Edap Tms is more favorable than RxSight.

Valuation & Earnings

This table compares Edap Tms and RxSight”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Edap Tms $65.82 million 2.61 -$20.58 million ($0.57) -8.07
RxSight $139.93 million 2.41 -$27.45 million ($0.88) -9.33

Edap Tms has higher earnings, but lower revenue than RxSight. RxSight is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

62.7% of Edap Tms shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 0.2% of Edap Tms shares are owned by company insiders. Comparatively, 9.6% of RxSight shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Edap Tms and RxSight’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Edap Tms -30.95% -61.60% -26.70%
RxSight -25.15% -12.82% -11.44%

Summary

RxSight beats Edap Tms on 8 of the 14 factors compared between the two stocks.

About Edap Tms

(Get Free Report)

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

About RxSight

(Get Free Report)

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.